NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Palifermin

Last Revision: December 21, 2020.

Estimated reading time: 1 minute

CASRN: 162394-19-6

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of palifermin during breastfeeding. Because palifermin is a large protein molecule with a molecular weight of 16,300 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. With an average half-life of 4.5 hours, the drug should be eliminated by the mother in 2 days. Because it is administered with potent chemotherapy agents, the persistence of those drugs is probably more relevant. The manufacturer recommends that breastfeeding should be discontinued during treatment with palifermin and for at least 2 weeks after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Palifermin

CAS Registry Number

162394-19-6

Drug Class

Breast Feeding

Lactation

Fibroblast Growth Factors

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Similar articles in PubMed

  • Review Enfortumab Vedotin[Drugs and Lactation Database (...]
    Review Enfortumab Vedotin
    . Drugs and Lactation Database (LactMed). 2006
  • Review Tafasitamab[Drugs and Lactation Database (...]
    Review Tafasitamab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Nivolumab[Drugs and Lactation Database (...]
    Review Nivolumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Rasburicase[Drugs and Lactation Database (...]
    Review Rasburicase
    . Drugs and Lactation Database (LactMed). 2006
  • Review Obinutuzumab[Drugs and Lactation Database (...]
    Review Obinutuzumab
    . Drugs and Lactation Database (LactMed). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...